Fabry disease is a rare, inherited disorder caused by a deficiency of the enzyme alpha-galactosidase A. Treatment for Fabry disease typically involves enzyme replacement therapy (ERT) with agalsidase alfa (Fabrazyme) or agalsidase beta (Replagal). ERT helps to reduce the buildup of globotriaosylceramide (GL-3) in the body, which is the main cause of the symptoms of Fabry disease. Other treatments may include medications to reduce pain, kidney dialysis, and organ transplantation.